← Back to Search

Palliative Transfusions for Blood Cancer (PalliaQOL Trial)

Q: Are there still positions available in this clinical trial for volunteers?

<p>Affirmative. Clinicaltrials.gov verifies that this research project, which was initially posted on August 14th 2020, is now looking for 20 volunteers from one medical centre.</p>

Q: What is the upper limit of participants for this research endeavor?

<p>Affirmative. According to clinicaltrials.gov, the trial which was originally publicized on August 14th 2020 is currently recruiting subjects. This study requires 20 participants from a single site.</p>

N/A

Waitlist Available

Led By Jennifer Holter, MD

Research Sponsored by University of Oklahoma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients wanting to enroll in hospice.

All patients >= 18 years with a primary diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myelomonocytic leukemia (CMML), 'high risk' Non-Hodgkin's Lymphoma (NHL), multiple myeloma (MM) and Myelodysplastic Syndrome (MDS) with a life expectancy of < 6 months who are transfusion dependent. Criteria for transfusion dependence is Symptom Questionnaire symptom grade 2 or higher. The Symptom Questionnaire is based on CTCAE (Common Terminology Criteria for Adverse Events) v5.0, with criteria modified for palliative care patients.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

PalliaQOL Trial Summary

This trial will study whether blood transfusions can help improve symptoms and quality of life for hospice patients.

Who is the study for?

This trial is for adults over 18 with certain blood cancers like AML, ALL, CLL, CMML, 'high risk' NHL, MM or MDS who need regular transfusions and have less than 6 months to live. They must want hospice care and either have an IV line or agree to get one.Check my eligibility

What is being tested?

The study tests if blood and platelet transfusions can help improve symptoms and life quality for hospice patients with specific blood cancers. It involves regular CBC collections to monitor the impact of these transfusions.See study design

What are the potential side effects?

Potential side effects may include reactions at the infusion site, allergic responses to the transfused blood products, fatigue from the procedure itself, or complications related to having an IV line.

PalliaQOL Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am considering enrolling in hospice care.

Select...

I am 18 or older with a specific blood cancer and need regular blood transfusions.

PalliaQOL Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of subjects with improved palliative efficacy after receiving transfusions.

Proportion of subjects with improved quality of life after receiving transfusions.

PalliaQOL Trial Design

1Treatment groups

Experimental Treatment

Group I: Tranfusions and blood collectionExperimental Treatment2 Interventions

Patients enrolled will receive one unit each of blood and/or platelet transfusions once a week based on trigger symptoms of anemia and/or thrombocytopenia, along with blood sample collections. Data on patient demographics, disease, and length of hospice stay will also be collected.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Blood and/or platelet transfusion

2020

N/A

~20

Complete blood count (CBC) collection

2020

N/A

~20

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor

455 Previous Clinical Trials

97,590 Total Patients Enrolled

Jennifer Holter, MDPrincipal InvestigatorUniversity of Oklahoma

2 Previous Clinical Trials

73 Total Patients Enrolled

Media Library

Blood and/or platelet transfusion Clinical Trial Eligibility Overview. Trial Name: NCT04454723 — N/A

Blood Cancers Research Study Groups: Tranfusions and blood collection

Blood Cancers Clinical Trial 2023: Blood and/or platelet transfusion Highlights & Side Effects. Trial Name: NCT04454723 — N/A

Blood and/or platelet transfusion 2023 Treatment Timeline for Medical Study. Trial Name: NCT04454723 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still positions available in this clinical trial for volunteers?

"Affirmative. Clinicaltrials.gov verifies that this research project, which was initially posted on August 14th 2020, is now looking for 20 volunteers from one medical centre."

Answered by AI

What is the upper limit of participants for this research endeavor?

"Affirmative. According to clinicaltrials.gov, the trial which was originally publicized on August 14th 2020 is currently recruiting subjects. This study requires 20 participants from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice

2020. "Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04454723.